Drug intelligence / Profile preview

YN401

Development stage: Preclinical
Lead developer: Innogen

Overview

YN401 is an investigational drug candidate currently in the preclinical stage of development by Guangzhou Yinnuo Pharmaceutical (also known as Innogen). It is being developed for the treatment of Type 1 Diabetes (T1D). The drug's mechanism of action is reported to involve the modulation of signaling pathways that provide protection to pancreatic β-cells. By preserving the survival and function of these insulin-producing cells, YN401 aims to address the underlying pathology of T1D, which is characterized by the autoimmune destruction of β-cells. As of early 2024, specific details regarding the molecular target, modality, and chemical structure of YN401 have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on YN401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YN401.

Explore the full profile